Pharmacokinetics of cotinine in rats: A potential therapeutic agent for disorders of cognitive function

Pei Li, Wayne D. Beck, Patrick Michael Callahan, Alvin V Terry, Michael G. Bartlett

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Attention has been paid to cotinine (COT), one of the major metabolites of nicotine (NIC), for its pro-cognitive effects and potential therapeutic activities against Alzheimer's disease (AD) and other types of cognitive impairment. In order to facilitate pharmacological and toxicological studies on COT for its pro-cognitive activities, we conducted a pharmacokinetic (PK) study of COT in rats, providing important oral and intravenously (IV) PK information. Methods In this study, plasma samples were obtained up to 48 h after COT was dosed to rats orally and IV at a dose of 3 mg/kg. Plasma samples were prepared and analyzed using a sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalytical method, providing concentration profiles of COT and metabolites after oral and IV administrations. Results The data were fitted into a one-compartment model and a two-compartment model for the oral and IV groups, respectively, providing important PK information for COT including PK profiles, half-life, clearance and bioavailability. The results suggested fast absorption, slow elimination and high bioavailability of COT in rats. Conclusions Several important facts about the PK properties in rats suggested COT could be a potential pro-cognitive agent. Information about the pharmacokinetics of COT in rats revealed in this study is of great importance for the future studies on COT or potential COT analogs as agents for improving cognition.

Original languageEnglish (US)
Pages (from-to)494-500
Number of pages7
JournalPharmacological Reports
Volume67
Issue number3
DOIs
StatePublished - Jan 1 2015

Fingerprint

Cotinine
Cognition
Pharmacokinetics
Therapeutics
Biological Availability
Therapeutic Uses
Tandem Mass Spectrometry
Nicotine
Liquid Chromatography
Toxicology
Oral Administration
Half-Life
Alzheimer Disease
Pharmacology

Keywords

  • Cognition
  • Cotinine
  • Hydrophilic interaction chromatography
  • Pharmacokinetics
  • Tandem mass spectrometry

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacokinetics of cotinine in rats : A potential therapeutic agent for disorders of cognitive function. / Li, Pei; Beck, Wayne D.; Callahan, Patrick Michael; Terry, Alvin V; Bartlett, Michael G.

In: Pharmacological Reports, Vol. 67, No. 3, 01.01.2015, p. 494-500.

Research output: Contribution to journalArticle

@article{a25e4af7ee7d431bbafd46bb2b8473c1,
title = "Pharmacokinetics of cotinine in rats: A potential therapeutic agent for disorders of cognitive function",
abstract = "Background Attention has been paid to cotinine (COT), one of the major metabolites of nicotine (NIC), for its pro-cognitive effects and potential therapeutic activities against Alzheimer's disease (AD) and other types of cognitive impairment. In order to facilitate pharmacological and toxicological studies on COT for its pro-cognitive activities, we conducted a pharmacokinetic (PK) study of COT in rats, providing important oral and intravenously (IV) PK information. Methods In this study, plasma samples were obtained up to 48 h after COT was dosed to rats orally and IV at a dose of 3 mg/kg. Plasma samples were prepared and analyzed using a sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalytical method, providing concentration profiles of COT and metabolites after oral and IV administrations. Results The data were fitted into a one-compartment model and a two-compartment model for the oral and IV groups, respectively, providing important PK information for COT including PK profiles, half-life, clearance and bioavailability. The results suggested fast absorption, slow elimination and high bioavailability of COT in rats. Conclusions Several important facts about the PK properties in rats suggested COT could be a potential pro-cognitive agent. Information about the pharmacokinetics of COT in rats revealed in this study is of great importance for the future studies on COT or potential COT analogs as agents for improving cognition.",
keywords = "Cognition, Cotinine, Hydrophilic interaction chromatography, Pharmacokinetics, Tandem mass spectrometry",
author = "Pei Li and Beck, {Wayne D.} and Callahan, {Patrick Michael} and Terry, {Alvin V} and Bartlett, {Michael G.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.pharep.2014.12.004",
language = "English (US)",
volume = "67",
pages = "494--500",
journal = "Pharmacological Reports",
issn = "1734-1140",
publisher = "Polish Academy of Sciences Publishing House",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of cotinine in rats

T2 - A potential therapeutic agent for disorders of cognitive function

AU - Li, Pei

AU - Beck, Wayne D.

AU - Callahan, Patrick Michael

AU - Terry, Alvin V

AU - Bartlett, Michael G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background Attention has been paid to cotinine (COT), one of the major metabolites of nicotine (NIC), for its pro-cognitive effects and potential therapeutic activities against Alzheimer's disease (AD) and other types of cognitive impairment. In order to facilitate pharmacological and toxicological studies on COT for its pro-cognitive activities, we conducted a pharmacokinetic (PK) study of COT in rats, providing important oral and intravenously (IV) PK information. Methods In this study, plasma samples were obtained up to 48 h after COT was dosed to rats orally and IV at a dose of 3 mg/kg. Plasma samples were prepared and analyzed using a sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalytical method, providing concentration profiles of COT and metabolites after oral and IV administrations. Results The data were fitted into a one-compartment model and a two-compartment model for the oral and IV groups, respectively, providing important PK information for COT including PK profiles, half-life, clearance and bioavailability. The results suggested fast absorption, slow elimination and high bioavailability of COT in rats. Conclusions Several important facts about the PK properties in rats suggested COT could be a potential pro-cognitive agent. Information about the pharmacokinetics of COT in rats revealed in this study is of great importance for the future studies on COT or potential COT analogs as agents for improving cognition.

AB - Background Attention has been paid to cotinine (COT), one of the major metabolites of nicotine (NIC), for its pro-cognitive effects and potential therapeutic activities against Alzheimer's disease (AD) and other types of cognitive impairment. In order to facilitate pharmacological and toxicological studies on COT for its pro-cognitive activities, we conducted a pharmacokinetic (PK) study of COT in rats, providing important oral and intravenously (IV) PK information. Methods In this study, plasma samples were obtained up to 48 h after COT was dosed to rats orally and IV at a dose of 3 mg/kg. Plasma samples were prepared and analyzed using a sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalytical method, providing concentration profiles of COT and metabolites after oral and IV administrations. Results The data were fitted into a one-compartment model and a two-compartment model for the oral and IV groups, respectively, providing important PK information for COT including PK profiles, half-life, clearance and bioavailability. The results suggested fast absorption, slow elimination and high bioavailability of COT in rats. Conclusions Several important facts about the PK properties in rats suggested COT could be a potential pro-cognitive agent. Information about the pharmacokinetics of COT in rats revealed in this study is of great importance for the future studies on COT or potential COT analogs as agents for improving cognition.

KW - Cognition

KW - Cotinine

KW - Hydrophilic interaction chromatography

KW - Pharmacokinetics

KW - Tandem mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=84961343830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961343830&partnerID=8YFLogxK

U2 - 10.1016/j.pharep.2014.12.004

DO - 10.1016/j.pharep.2014.12.004

M3 - Article

C2 - 25933960

AN - SCOPUS:84961343830

VL - 67

SP - 494

EP - 500

JO - Pharmacological Reports

JF - Pharmacological Reports

SN - 1734-1140

IS - 3

ER -